Sharda Cropchem Strong Financial Performance for the Year Ended March 31, 2026

Sharda Cropchem Limited has announced its audited financial results for the year ended March 31, 2026. The company reported a significant growth in performance, achieving an annual revenue of Rs. 5,26,758 lakhs and a net profit of Rs. 68,099 lakhs. Reflecting this positive trajectory, the Board of Directors has recommended a final dividend of Rs. 9.00 per equity share for the financial year 2025-26, subject to shareholder approval.

Annual Financial Highlights

For the financial year ended March 31, 2026, Sharda Cropchem delivered robust financial results. The company reported total revenue from operations of Rs. 5,26,758 lakhs, compared to Rs. 4,31,985 lakhs in the previous fiscal year. The company’s profit after tax for the year stood at Rs. 68,099 lakhs, marking a substantial increase from the Rs. 30,441 lakhs recorded in the previous year.

Dividend Recommendation

Recognizing the company’s strong performance, the Board of Directors has recommended a final dividend of Rs. 9.00 per equity share (face value of Rs. 10.00 each) for the financial year 2025-26. This dividend is subject to the approval of shareholders at the company’s upcoming Annual General Meeting.

Segment Performance

The company’s operations are primarily divided into the Agrochemicals and Non-agrochemicals business segments. The Agrochemicals segment remains a dominant driver of performance, generating Rs. 4,71,685 lakhs in revenue for the year, while the Non-agrochemicals segment contributed Rs. 55,072 lakhs.

Operational Context

Management noted that the Agrochemicals segment is inherently seasonal, with performance influenced by global cropping patterns and weather conditions. Despite these fluctuations, the company has maintained steady operational health and successfully managed its portfolio of subsidiaries across multiple international markets.

Source: BSE

Previous Article

Colgate-Palmolive (India) Life Insurance Corporation Increases Stake to Over 5%

Next Article

GlaxoSmithKline Pharmaceuticals Full Year Results and Dividend Declaration for 2026